Showing 1 - 4 results of 4 for search 'Pablo Ryan-Murua', čas poizvedbe: 0.02s Refine Results
  1. 1
    DNA Methylation Levels of the ACE2 Promoter Are Not Associated with Post-COVID-19 Symptoms in Individuals Who Had Been Hospitalized Due to COVID-19

    DNA Methylation Levels of the ACE2 Promoter Are Not Associated with Post-COVID-19 Symptoms in Individuals Who Had Been Hospitalized Due to COVID-19 od César Fernández-de-las-Peñas, Gema Díaz-Gil, Antonio Gil-Crujera, Stella M. Gómez-Sánchez, Silvia Ambite-Quesada, Juan Torres-Macho, Pablo Ryan-Murua, Anabel Franco-Moreno, Oscar J. Pellicer-Valero, Lars Arendt-Nielsen, Rocco Giordano

    Izdano 2024-06-01
    Polni tekst
    Article
  2. 2
    Post-COVID-19 Pain Is Not Associated with DNA Methylation Levels of the <i>ACE2</i> Promoter in COVID-19 Survivors Hospitalized Due to SARS-CoV-2 Infection

    Post-COVID-19 Pain Is Not Associated with DNA Methylation Levels of the <i>ACE2</i> Promoter in COVID-19 Survivors Hospitalized Due to SARS-CoV-2 Infection od César Fernández-de-las-Peñas, Gema Díaz-Gil, Antonio Gil-Crujera, Stella M. Gómez-Sánchez, Silvia Ambite-Quesada, Anabel Franco-Moreno, Pablo Ryan-Murua, Juan Torres-Macho, Oscar J. Pellicer-Valero, Lars Arendt-Nielsen, Rocco Giordano

    Izdano 2024-07-01
    Polni tekst
    Article
  3. 3
    Inflammatory Polymorphisms (IL-6 <i>rs1800796</i>, IL-10 <i>rs1800896</i>, TNF-α <i>rs1800629</i>, and IFITM3 <i>rs12252</i>) Are Not Associated with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors

    Inflammatory Polymorphisms (IL-6 <i>rs1800796</i>, IL-10 <i>rs1800896</i>, TNF-α <i>rs1800629</i>, and IFITM3 <i>rs12252</i>) Are Not Associated with Post-COVID Symptoms in Previou... od César Fernández-de-las-Peñas, Gema Díaz-Gil, Antonio Gil-Crujera, Stella M. Gómez-Sánchez, Silvia Ambite-Quesada, Juan Torres-Macho, Pablo Ryan-Murua, Ana I. Franco-Moreno, Oscar J. Pellicer-Valero, Lars Arendt-Nielsen, Rocco Giordano

    Izdano 2024-02-01
    Polni tekst
    Article
  4. 4
    Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms?

    Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms? od César Fernández-de-las-Peñas, Anabel Franco-Moreno, María Ruiz-Ruigómez, Estibaliz Arrieta-Ortubay, Pablo Ryan-Murua, Carlos Lumbreras-Bermejo, Pablo del-Valle-Loarte, Oscar J. Pellicer-Valero, Rocco Giordano, Lars Arendt-Nielsen, Isabel Martín-Garrido, Juan Torres-Macho

    Izdano 2024-06-01
    Polni tekst
    Article

Iskalna orodja: